U.S. markets close in 2 hours 5 minutes
  • S&P 500

    3,669.02
    +83.40 (+2.33%)
     
  • Dow 30

    29,428.85
    +703.34 (+2.45%)
     
  • Nasdaq

    10,783.00
    +207.38 (+1.96%)
     
  • Russell 2000

    1,705.58
    +40.86 (+2.45%)
     
  • Crude Oil

    83.33
    +3.84 (+4.83%)
     
  • Gold

    1,705.50
    +33.50 (+2.00%)
     
  • Silver

    20.69
    +1.66 (+8.70%)
     
  • EUR/USD

    0.9792
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    3.6370
    -0.1670 (-4.39%)
     
  • GBP/USD

    1.1267
    +0.0101 (+0.90%)
     
  • USD/JPY

    144.6380
    -0.0910 (-0.06%)
     
  • BTC-USD

    19,550.83
    +340.31 (+1.77%)
     
  • CMC Crypto 200

    444.78
    +9.43 (+2.17%)
     
  • FTSE 100

    6,908.76
    +14.95 (+0.22%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

Kymera's KT-474 Achieved Sustained IRAK4 Reduction After Single Dose In Healthy Volunteers

·1 min read
  • Kymera Therapeutics Inc (NASDAQ: KYMR) has announced interim results from the Single Ascending Dose (SAD) portion of the Phase 1 trial of KT-474 in healthy volunteers.

  • KT-474 has exceeded the Phase 1 target degradation of 85% to date, with robust IRAK4 degradation after a single oral dose lasting for at least six days at all dose levels.

  • No treatment-related adverse events have been observed to date.

  • Also, the FDA has lifted the partial clinical hold on the Multiple Ascending Dose (MAD) portion of the Phase 1 trial of KT-474. Kymera plans to initiate repeat dosing in July 2021.

  • A subsequent cohort in the Phase 1 trial will include up to 20 patients with atopic dermatitis and hidradenitis suppurativa.

  • Kymera expects to present updated results from the healthy volunteer SAD and MAD portions of the trial in Q4 of 2021.

  • Kymera will host a conference call and webcast today at 8:00 a.m. ET.

  • Price Action: KYMR shares are up 8.16% at $48 in the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.